Chemed Corp: stock overview

CHENYSEHealthcare · Services-Home Health Care Services

Price

$548.20

November 13, 2026Market cap $7.1B

What Ploutos Investor adds for Chemed

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Chemed had revenue of $2.7B over the last 12 months and net income of $282M, a net margin of 10.6%. Revenue grew by 4.0% a year on average over the last 5 years. At $548.20 the shares trade at a P/E of 25.3, against a median of 30.9 over the last 5 fiscal years. It has net debt of $188M. It pays a dividend yielding 0.46%.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$7.1B
13.01M shares
P/E
25.3
Today25.3
Median30.9
Revenue, 12 months
$2.7B
+4.0% a year over 5 years
Net margin
10.6%
2025: 0.0%, above 51% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+5.7% a year over 2 years

  • 202510-K
    Revenue$2.5B
  • 202410-K
    Revenue$2.4B
  • 202310-K
    Revenue$2.3B

Fiscal years in figures

CHE's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $7.8B
$7.1B
Enterprise value 
$7.3B
P/E 3-year median: 26.6
25.3
EV / EBIT 
19.7
EV / Revenue 
2.8
P/B 3-year median: 6.9
8.3
FCF yield 3-year median: 4.7%
4.1%
Earnings yield 3-year median: 3.8%
4.0%

Profitability

Gross margin 
33.5%
Operating margin 
13.9%
Net margin 3-year median: 12.0%
10.6%
ROIC 
26.5%
ROIC, 5-year average 
28.2%
ROE 
30.7%

Growth

Revenue, yearly change 
+4.1%
EPS, yearly change 
-7.8%
FCF, yearly change 
-11.6%
Revenue, average a year 
+4.0%
EPS, average a year 
-1.2%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$48M
Total debt 
$392M
Of which operating leases 
$156M
Net debt 
$188M
Net debt / EBITDA 
0.4x
Interest cover 
75.4x
Current ratio 
1.11

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 0.3%
0.46%
Buybacks 
6.05%
Total returned 
6.51%
Shares, yearly change 
-5.9%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 80).

Operating margin

13.4%

Above 90% of the 62 companies in its industry, and 72% of all.

Net margin

0.0%

Above 51% of the 68 companies in its industry, and 34% of all.

ROE

0.0%

Above 46% of the 58 companies in its industry, and 31% of all.

ROA

0.0%

Above 50% of the 69 companies in its industry, and 35% of all.

Revenue growth

4.1%

Above 27% of the 68 companies in its industry, and 42% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
CHEMED CORP
Exchange
NYSE
Industry (SIC)
8082 · Services-Home Health Care Services
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
13.01M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Chemed's filings show?

These are Chemed's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about CHE

Didn't find what you were looking for?

Ask us
What is CHE's market cap?

Chemed Corp's market cap is $7.1B, at a price of $548.20 on November 13, 2026 and 13.01M shares.

What is CHE's P/E?

CHE's P/E is 25.3, on earnings per share of $20.87 over the last 12 months. The median over the last 5 fiscal years was 30.9.

How much revenue does CHE have?

Chemed had revenue of $2.7B over the last 12 months. Over the last 5 years it changed by +4.0% a year on average.

Does CHE pay a dividend?

Yes. Chemed paid $2.50 per share over the last 12 months, a yield of 0.46% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Chemed Corp's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.